...
机译:A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
UCL, Dept Renal Med, London, England;
UT Southwestern Med Ctr, Dept Internal Med, Dallas, TX USA;
AstraZeneca, Biopharmaceut R&D, Late Stage Dev Cardiovasc Renal & Metab, Gothenburg, SwedenUniv Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, NetherlandsStanford Univ, Sch Med, Dept Med, Stanford, CA USAUniv Utah Hlth Sci, Study Design & Biostat Ctr, Salt Lake City, UT USASouthern Med Univ, Nanfang Hosp, Natl Clin Res Ctr Kidney Dis, Div Nephrol, Guangzhou, Peoples RUniv Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, ScotlandArbor Res Collaborat Hlth, Ann Arbor, MI USANatl Med Sci & Nutr Inst Salvador Zubiran, Mexico City, DF, MexicoSteno Diabet Ctr Copenhagen, Gentofte, DenmarkHenry Ford Hosp, Div Nephrol & Hypertens, Detroit, MI USA;
chronic kidney disease; dapagliflozin; DAPA-CKD; IgA nephropathy; randomized controlled clinical trial; sodium-glucose cotransporter inhibitor;